Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL702758 | 0.90 | ALDH1A1 (0.46) | ALDH1A1HTTMAPK1MAPTTDP1 | |
| SCHEMBL701283 | 0.88 | ALDH1A1 (0.44) | ALDH1A1HTTMAPK1MAPTSMN1; SMN2 | |
| SCHEMBL702311 | 0.86 | ALDH1A1 (0.44) | ALDH1A1HTTMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL702893 | 0.83 | KMT2A (0.45) | ALDH1A1HTTNPC1RAB9ATP53 | |
| SCHEMBL10166779 | 0.83 | ALDH1A1 (0.41) | ALDH1A1HTTMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL733801 | 0.82 | KMT2A (0.41) | ALDH1A1HTTNPC1RAB9ATP53 | |
| SCHEMBL751192 | 0.82 | CYP1A2 (0.48) | ALDH1A1HTTMAPK1SMN1; SMN2TP53 | |
| SCHEMBL704658 | 0.82 | ALDH1A1 (0.40) | ALDH1A1HTTMAPK1SMN1; SMN2NPC1 | |
| SCHEMBL731676 | 0.81 | CYP2C9 (0.42) | ALDH1A1HTTMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL700323 | 0.81 | CYP1A2 (0.37) | ALDH1A1HTTMAPK1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102099342-B | Aminotetrahydroindazoloacetic acids | HOFFMANN LA ROCHE | 2013-07-10 | — | — | CN | claimed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | claimed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | claimed |
| JP-2011528002-A | — | — | 2011-11-10 | — | — | JP | claimed |
| CN-102099342-A | Aminotetrahydroindazoloacetic acids | HOFFMANN LA ROCHE | 2011-06-15 | — | — | CN | claimed |
| EP-2307382-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | claimed |
| WO-2010006939-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | claimed |
| CN-102099342-B | Aminotetrahydroindazoloacetic acids | HOFFMANN LA ROCHE | 2013-07-10 | — | — | CN | disclosed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268870-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI (CN) | 2012-04-19 | — | — | US | disclosed |
| US-8124641-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307382-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2011-12-21 | — | — | EP | disclosed |
| CN-102099342-A | Aminotetrahydroindazoloacetic acids | HOFFMANN LA ROCHE | 2011-06-15 | — | — | CN | disclosed |
| EP-2307382-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| WO-2010006939-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095053-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | ALDH1A1 317/4885HTT 3176/4885MAPK1 3004/4885 |
| US-20100016368-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | ALDH1A1 317/4885HTT 3176/4885MAPK1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.